Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wumeiwan Jiawei Fang for Idiopathic Blepharospasm
NCT05618470Phase 3Unknown
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Jan 2018
- Primary completion
- Aug 2024
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of wumeiwan jiawei fang in benign essential blepharospasm (BEB) (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoints: Jankovic Rating Scale at 6 months, Blepharospasm Disability Index at 6 months and 4 more. Status: unknown.
02
Drugs
wumeiwan jiawei fang
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT05618470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618470.